NEW YORK, June 5 - Ingenium Pharmaceuticals has signed an agreement with
The companies did not disclose the financial terms of the agreement.
The project will use Ingenium's genotyping platform to create mammalian models that carry alterations in target genes. Oxagen has identified genes relating to metabolic diseases using its target identification technology.
Ingenium is based in